Rinvoq®(upadacitinib) – New indication
March 16, 2022 - AbbVie announced the FDA approval of Rinvoq (upadacitinib), for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.
Top